Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and match enough to tolerate FCR therapy, should still be excellent candidates for the latter, Together with the advantage remaining that this treatment method is usually accomplished in six months while ibrutinib must be taken indefinitely. This selection could well be significa